

AFFIMER[®] TECHNOLOGY

Next-generation biotherapeutics to surpass limitations of cancer therapies

DELIVERING NEXT-GENERATION BIOTHERAPEUTICS

Avacta's proprietary Affimer[®] technology is a novel class of small molecule entities, based on the naturally occurring human protein Stefin A, which enables the delivery of next-generation biotherapeutics.

Affimer[®] proteins (MW 14kDa) are around 10x smaller than antibodies, offering significant tissue penetration advantages in solid tumours. This, combined with strong stability and high expression, confers excellent drug-like properties to Affimer molecules.


The PK/PD of therapeutic Affimers can be tuned using Affimer[®] XT, a serum albumin-binding Affimer with half-life extension properties, or using Affimer-Fc fusions. Affimer[®] proteins can also be genetically fused to each other to form multi-specific therapies, or to other proteins, such as the C-terminus of an antibody, to generate bispecific biobetter formats.

Avacta has provided further pre-clinical proof of concept in its joint venture with Daewoong, called AffyXell. AffyXell develops mesenchymal stem cell-based therapies expressing Affimers to improve cell-based treatments for patients with immune-related conditions.

AVACTA THERAPEUTICS

Avacta Therapeutics is a clinical-stage pioneer of next-generation cancer therapies, with a mission to transform treatment outcomes for cancer patients.

Avacta's novel cancer therapies harness its proprietary technology – the innovative preCISION™ platform for tumour-targeted chemotherapy and novel Affimer[®] biotherapeutics platform – to deliver first-in-class cancer therapies that boost efficacy and minimise off-target toxicity. With this approach, Avacta is building a pipeline of novel cancer therapies with the potential to revolutionise the treatability of solid tumours.



AFFIMER[®] AT A GLANCE

Key advantages

- Affimer[®] proteins are 10x smaller than antibodies for greater tissue penetration in solid tumours
- Stability and high expression – ideal for gene delivery
- Tuneable PK/PD – rapid clearance from the body if there is no target engagement
- Quick to develop and simple to manufacture
- Platform to develop Bispecifics and Multispecifics
- Unrelated to antibodies, creating freedom to operate where antibody-based IP exists

Affimer[®]

Avacta has partnered with LG Chem for its lead Affimer[®] programme, a PD-L1 XT Affimer[®] antagonist which is in pre-clinical development. Avacta is also developing a robust pipeline of future Affimer bispecifics.

For more information:
www.avacta.com/therapeutics